ABU DHABI, October 28, 2014 /PRNewswire/ --
PharmaEDGE, a unique Continuing Professional Development (CPD)
Program for pharmacists of Middle
East and North African (MENA) countries was organized in
Abu Dhabi, UAE recently. The
initiative was supported with an academic grant by Glenmark
Pharmaceuticals Ltd, a leading research-based global
pharmaceuticals company with operations in over 90 countries
including the Gulf countries.
(Photo:
http://photos.prnewswire.com/prnh/20141028/713293 )
(Logo:
http://photos.prnewswire.com/prnh/20130626/625083 )
PharmaEDGE was an Interactive Continuous Pharmacy Education
program developed in accordance with Accreditation Council for
Pharmacy Education (ACPE) and Emirates Medical Education (EMA). The
objective of PharmaEDGE was to enhance the knowledge, skills and
competence of pharmacists which will ultimately lead to improvement
in patient and public health outcomes.
The faculty included leading global as well as local experts
from UAE who shared their perspective on the latest
state-of-the-art research advances over a wide spectrum of topics
such as optimal clinical management of chronic disease, utilizing
best practice guideline, reduction of medication error, patient
compliance and adherence, acute pain management and current and
future role of pharmacist in healthcare system.
PharmaEDGE was chaired by Dr Mariam
Galadari - Chairperson Pharmacy Division-Emirates
Medical Association. The International keynote speaker of
PharmaEDGE was Prof. Geoffrey Wall from
Drake University, USA. The key messages that Dr Wall emphasized
was the importance of pharmacist in patient education to optimize
treatment and clinical management of chronic disease and also
intervention of pharmacists to reduce medication errors.
Prof. Tariq I Mughal, from Tufts Medical Centre,
Boston was the program director of
PharmaEDGE. Prof. Mughal spoke about treatment adherence and
compliance. He mainly emphasized on the role of pharmacists in
patient compliance and patient education to ensure adherence to the
treatment.
Dr Nehad M Hamoudi from Gulf Medical University,
Ajman, UAE presented a case about
drug interaction and also mentioned the importance of understanding
drug interactions, as in today's practise, doctors usually
co-prescribe medications.
Dr Sathvik B Sridhar from Medical and Health Sciences
University, Ras Al Khaimah, UAE,
spoke about the role of pharmacists in adverse drug reaction
monitoring with the help of case study presentations. Dr Sathvik
also helped the audience understand the errors in identifying an
adverse reaction and reporting of such a reaction.
The symposium was also graced with the presence of Dr
Azad Moopen. Dr Azad Moopen, who is the founder of Aster Group
(Chain of Pharmacies and hospitals), shared his experience and gave
deep insight about topical challenges in pharmacy establishment in
MENA region. He also shared his views on the evolution of
E-prescription and the impact it will have on pharmacist's
practice. Dr Moopen also addressed various queries of the audience
and explained to them the importance of being a pharmacist,
continuous medical education of the pharmacist and what difference
a can pharmacist make in the treatment process.
PharmaEDGE was a successful event with 362 pharmacists attending
the programme. All the speakers, panelist and attendees appreciated
the symposium and congratulated the organizers and Glenmark for
such a successful and unique initiative for pharmacists in the MENA
region
About Glenmark
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven,
global, integrated pharmaceutical company and ranked among the top
80 pharma and biotech companies of the world in terms of revenues
as per SCRIP 100 Rankings. Glenmark is a leading player in the
discovery of new molecules both NCEs and NBEs. Glenmark has several
molecules in various stages of clinical development and primarily
focused in the areas of inflammation, pain and oncology. The
company has significant presence in branded formulations across
emerging economies including India. Its subsidiary, Glenmark Generics
Limited services the requirements of the US and Western Europe markets.